Consolidation and growth are happening in the office-based opioid treatment (OBOT) sector of the addiction treatment industry despite broader trends of market slowdown in the space. OBOT models originated as a way to make medication-assisted treatment (MAT) with buprenorphine, methadone and naltrexone more accessible by bringing it into a less stigmatized medical environment. These models are still ripe with opportunity for scaling and innovating care, industry professionals told Behavioral Health Business at INVEST 2025 in October. “I actually think we are in a growth stage and a consolidation stage,” Steve Priest, co-founder and CEO at Spero Health, said during INVEST.
Read the full article: OBOT Industry Scales Up, Yet Sustainable Success Hinges on Payer Partnerships //
Source: https://bhbusiness.com/2025/12/17/obot-industry-scales-up-yet-sustainable-success-hinges-on-payer-partnerships/